Report
EUR 236.14 For Business Accounts Only

Q3 figures, Another disaster

Q3 sales continued in the same downward trend as H1, dropping by 27.1% to JOD2.7M. Till September, the revenues decreased by 17.3% yoy, from JOD9.6M to JOD8M. The net profit improved slightly from a loss of JOD9.97M to JOD-9.78M. The funding sources of the company are being reduced from JOD23.8M in December 2014, to JOD18M in September 2015.
Underlying
Jordanian Pharmaceutical Manufacturing

Provider
AlphaMena Corporate Services
AlphaMena Corporate Services

AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.

Other Reports on these Companies
Other Reports from AlphaMena Corporate Services

ResearchPool Subscriptions

Get the most out of your insights

Get in touch